Lantern Pharma Inc.

NASDAQ: LTRN · Real-Time Price · USD
4.61
0.04 (0.88%)
At close: Aug 15, 2025, 3:59 PM
4.66
1.08%
After-hours: Aug 15, 2025, 04:32 PM EDT

Company Description

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process.

Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer.

The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma.

In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways.

Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment.

Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data.

The company was incorporated in 2013 and is headquartered in Dallas, Texas.

Lantern Pharma Inc.
Lantern Pharma Inc. logo
Country United States
IPO Date Jun 11, 2020
Industry Biotechnology
Sector Healthcare
Employees 24
CEO Panna Sharma

Contact Details

Address:
1920 McKinney Avenue
Dallas, Texas
United States
Website https://www.lanternpharma.com

Stock Details

Ticker Symbol LTRN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001763950
CUSIP Number 51654W101
ISIN Number US51654W1018
Employer ID 46-3973463
SIC Code 2834

Key Executives

Name Position
Panna Sharma President, Chief Executive Officer & Director
David R. Margrave Chief Financial Officer & Secretary
Dr. Kishor Gopaldas Bhatia Ph.D. Chief Scientific Officer & Scientific Consultant
Dr. Marc C. Chamberlain M.D. Chief Medical Officer of Starlight Therapeutics
Dr. Peter L. Nara D.V.M., M.S., Ph.D. Co-Founder & Advisor
Ernest Kitt B.S., M.S Head of Clinical Operations

Latest SEC Filings

Date Type Title
Aug 13, 2025 8-K Current Report
Aug 13, 2025 10-Q Quarterly Report
Aug 11, 2025 ARS Filing
Aug 08, 2025 DEF 14A Filing
Jul 30, 2025 3 Filing
Jul 29, 2025 8-K Current Report
Jul 28, 2025 PRE 14A Filing
Jul 03, 2025 8-K Current Report
Jul 03, 2025 424B5 Filing
Jun 13, 2025 4 Filing